AMWAY (MALAYSIA) HOLDINGS BERHAD

FY2023 ANALYST BRIEFING

29 February 2024

FINANCIAL

PERFORMANCE

Ng Ai Lee, Chief Financial Officer

Our Performance

Sales Revenue

Profit Before Tax

Net Profit

RM 1,408.3million

RM 152.6million

RM 115.9 million

Sales Revenue

1,400

1,600

7.0% vs PY

1,200

1,000

800

600

FY2023 RM1,408.3 million | FY2022 RM 1,514.8 million

400

200

-

Sales decline due to:

  • On the back of exceptional growth in year 2020 & 2021 and a marginal growth in FY2022;
  • Weaker demand for health & wellness products & home appliances.
  • Surge in inflationary pressure dampening consumer sentiment and spending ability; and
  • Consumer priorities shifting away from pandemic-specific health concerns.

Sales (RM' Million)

1,4861,515

1,408

+29%

1,153

966

+19%

+2%

-7%

2019

2020

2021

2022

2023

Sales

Growth Rate

35%

30%

25%

20%

15%

10%

5%

0%

-5%

-10%

Profit Before Tax (RM'mil)

10.80%

6.80%

152.6

103.1

FY2022

FY2023

Profit Margin (PBT/Sales)

Profit Before Tax (PBT)

The significantincrease in PBT (48.0%) is mainly attributableto:

  • Lower ABO incentives payout in tandem with lower sales; and
  • Price increase.

48.0% vs PY

+4.0% profitability

FY2023RM152.6 million | FY2022 RM103.1 million

70

60

50

40

sen

30

20

10

0

Dividend

107%

60.0

81% 84%

38.0

40

24.018

4

202020

FY2021

FY2022

FY2023

Interim Dividend

Special Dividend

Payout Ratio

Dividend Payout

Dividendpolicy:

Dividend payout ratio of no less than 80% of current year's net earnings

Dividendpayout 2023:

  • Totaldividend : 60.0sen (2022:38.0 sen)
  • Dividend payout: RM98.6mil (2022: RM62.5mil)

BUSINESS

HIGHLIGHTS

Last Year…

Post

Ongoing

Inflation, FX

Pandemic

Conflict

Impact, Petrol

Impact to Direct Selling Industry?

In Globe

SALES VS PRIOR YEAR

Amway

(1.4%)

Peer Set Mean

(9.3%)

Herbalife

(3.4%)

NuSkin*

(14.0%)

D I R E C T

Natura*

2.0%

S E L L I N G

Medifast

(25.9%)

P E E R S E T

Oriflame

(9.0%)

USANA

(5.2%)

Q2 2023 (YTD)

2022

2023 Constant Dollar

In Malaysia

-10% to -60% Decline

Projected for some Malaysian

Direct Selling Companies

*Includes non-direct selling businesses

Amway Malaysia's Growth Journey: After Exponential Growth

+29%

+2%

Decline

7%

Unit: M RM

+19%

1,485

1,515

1,408

1,154

966

FY19

FY20

FY21

FY22

FY23

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Amway (M) Holdings Bhd published this content on 29 February 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 March 2024 04:14:07 UTC.